Thermo Fisher Scientific Inc. $TMO Shares Bought by Sava Infond d.o.o.

Sava Infond d.o.o. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,390 shares of the medical research company’s stock after buying an additional 1,000 shares during the quarter. Sava Infond d.o.o.’s holdings in Thermo Fisher Scientific were worth $2,614,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Raiffeisen Bank International AG grew its stake in shares of Thermo Fisher Scientific by 48.7% during the 3rd quarter. Raiffeisen Bank International AG now owns 159,161 shares of the medical research company’s stock worth $73,539,000 after purchasing an additional 52,118 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Thermo Fisher Scientific by 0.7% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 5,107 shares of the medical research company’s stock worth $2,477,000 after buying an additional 36 shares in the last quarter. Bridgewater Advisors Inc. increased its holdings in Thermo Fisher Scientific by 1.6% in the third quarter. Bridgewater Advisors Inc. now owns 2,388 shares of the medical research company’s stock valued at $1,158,000 after buying an additional 38 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Thermo Fisher Scientific in the third quarter worth about $1,924,000. Finally, Mendel Money Management boosted its stake in shares of Thermo Fisher Scientific by 1.0% during the 3rd quarter. Mendel Money Management now owns 11,413 shares of the medical research company’s stock worth $5,536,000 after acquiring an additional 109 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.8%

Shares of TMO opened at $510.96 on Friday. The firm’s fifty day moving average is $579.25 and its two-hundred day moving average is $545.43. The stock has a market cap of $191.97 billion, a PE ratio of 28.80, a price-to-earnings-growth ratio of 2.97 and a beta of 0.93. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. During the same period last year, the firm posted $6.10 earnings per share. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TMO. Stifel Nicolaus upped their price target on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a report on Friday, January 9th. TD Cowen cut their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research report on Friday, January 30th. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Finally, Citigroup lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $633.68.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Frederick M. Lowery sold 6,913 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $597.68, for a total value of $4,131,761.84. Following the transaction, the executive vice president owned 14,367 shares in the company, valued at approximately $8,586,868.56. The trade was a 32.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 108,996 shares of company stock valued at $63,355,935. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.